Observational Evaluation of Atopic Dermatitis in Pediatric Patients
Dermatitis AtopicPrimary Objectives:
* To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable.
* To evaluate the time-course of AD and selected atopic comorbidities.
Secondary Objectives:
* To characterize disease burden and unmet need.
* To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching).
* To document the real-world effectiveness and safety of treatments.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
0 to 11
Participation Criteria
Inclusion criteria:
* Patients with moderate to severe AD, according to the Investigator's assessment;
* Currently receiving systemic treatment (including phototherapy) for atopic dermatitis or currently on topical treatment, but otherwise candidates for systemic treatment.
Exclusion criteria:
* Concurrent participation in an interventional clinical trial which modifies patient care.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Location
Investigational Site Number : 1240004
Investigational Site Number : 1240004Calgary, Alberta
Canada
Contact Study Team
Investigational Site Number : 1240001
Investigational Site Number : 1240001Markham, Ontario
Canada
Contact Study Team
Investigational Site Number : 1240010
Investigational Site Number : 1240010Halifax, Nova Scotia
Canada
Contact Study Team
Investigational Site Number : 1240009
Investigational Site Number : 1240009Regina, Saskatchewan
Canada
Contact Study Team
Investigational Site Number : 1240005
Investigational Site Number : 1240005Winnipeg, Manitoba
Canada
Contact Study Team
Investigational Site Number : 1240006
Investigational Site Number : 1240006Montreal, Quebec
Canada
Contact Study Team
Investigational Site Number : 1240007
Investigational Site Number : 1240007Calgary, Alberta
Canada
Contact Study Team
Investigational Site Number : 1240008
Investigational Site Number : 1240008Toronto, Ontario
Canada
Contact Study Team
- Study Sponsored By
- Sanofi
- Participants Required
- More Information
- Study ID:
NCT03687359